Plavix's new generic status could be boon for patients

May 15, 2012 By Steven Reinberg, HealthDay Reporter in Medications

Plavix's new generic status could be boon for patients

Price of widely used blood thinner should drop once patent ends Thursday.

(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.

Adherence rates will improve as a result, and fewer patients will suffer from preventable , said Dr. Gregg Fonarow, a professor of medicine and director of the Ahmanson-UCLA Center in Los Angeles.

"This medication has helped millions of patients avoid fatal and non-fatal cardiovascular events," said Fonarow, who also is a spokesman for the . But its high cost has "contributed to patients not filling initial prescriptions for the drug and premature discontinuation of ," he said.

Patients who stop taking the drug prematurely may then face catastrophic consequences, including fatal cardiovascular events and strokes, he added.

Plavix works by helping prevent platelets in the blood from sticking together to form clots. The drug usually is taken along with aspirin, which acts as a blood thinner to prevent heart attack and stroke.

Plavix commonly is used by patients with heart-related chest pain, unstable heart disease or those who have had a stent implanted to open a blocked artery.

"The most important impact of the availability of generics will be to reduce costs for patients and health systems where clopidogrel is already indicated," said Dr. Ralph Sacco, chairman of neurology at the University of Miami School of Medicine and former president of the American Heart Association.

The drug doesn't work for everyone, however. Some patients cannot metabolize it, which reduces its effectiveness.

In addition, are available that may be better than Plavix, Fonarow said.

"Newer antiplatelet agents, such as prasugrel (Effient) and ticagrelor (Brilinta), have been shown to be more [effective] than clopidogrel, and for many patients these [drugs] may be a better choice, despite higher cost," Sacco said.

Sales of Plavix, made by Bristol-Myers Squibb, topped $9 billion in 2011. A generic version, at a much lower cost, is expected to eat into those sales dramatically. The drug already is sold as a generic by Sanofi in much of the European Union, according to the Associated Press.

Plavix currently can cost almost $200 a month, according to published reports. Generic versions are expected to cost much less.

To keep patients using brand-name Plavix rather than a generic version, the manufacturer is offering coupons that will bring down the cost.

Plavix, even in a less expensive version, can't replace other clot-preventing drugs, such as warfarin, in certain patients.

For example, Plavix is not recommended for patients with an irregular heartbeat, called atrial fibrillation, who take blood thinners to prevent strokes. A 2009 report in the New England Journal of Medicine said patients with atrial fibrillation who took were at an unacceptably high increased risk of severe bleeding.

"For patients with atrial fibrillation, anticoagulants like warfarin (Coumadin), dabigatran (Pradaxa) and rivaroxaban (Xarelto) are indicated, and clopidogrel is not an appropriate substitute," Fonarow said.

More information: For more information on Plavix, visit the U.S. National Institutes of Health.

Journal reference: New England Journal of Medicine search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created 4 hours ago | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created 6 hours ago | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created 12 hours ago | popularity not rated yet | comments 0

Succesful results in developing oral vaccine against diarrhea

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

Medications created 14 hours ago | popularity not rated yet | comments 0

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Medications created May 21, 2013 | popularity 4.2 / 5 (5) | comments 0


Slowing the aging process—only with antibiotics

Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...